Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (12)

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  2. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2019

  1. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: Results from 3 UK clinical trials

    Blood Advances, Vol. 3, Núm. 16, pp. 2474-2481

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2015

  1. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients

    PLoS ONE, Vol. 10, Núm. 4

2014

  1. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

    EMBO Molecular Medicine, Vol. 6, Núm. 4, pp. 539-550

  2. TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC

    Molecular Cancer Research, Vol. 12, Núm. 5, pp. 660-669

2012

  1. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung

    Journal of Clinical Oncology, Vol. 30, Núm. 10, pp. 1129-1136

2010

  1. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A

    Molecular Cancer, Vol. 9